Who makes GRT9906 PR tablet?

GRT9906 PR tablet is developed by Grünenthal GmbH.

What development phase is GRT9906 PR tablet in?

GRT9906 PR tablet is in Phase 1.

Last reviewed 2026-04-19 · How we verify

GRT9906 PR tablet

Grünenthal GmbH · Phase 1 active Small molecule

At a glance

Generic name	GRT9906 PR tablet
Sponsor	Grünenthal GmbH
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GRT9906 Prolonged Release Tablets After Dose Escalation in Healthy Subjects (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

GRT9906 PR tablet CI brief — competitive landscape report
GRT9906 PR tablet updates RSS · CI watch RSS
Grünenthal GmbH portfolio CI